Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for VECTIBIX
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
- Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial
- Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
- Anti-EGFR and Immunotherapy for TN-IBC
- Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
- Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
- Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
- Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
- Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal
- Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- Palbociclib and Cetuximab in Metastatic Colorectal Cancer
- PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
- A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment
- Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
- Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
- 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
- FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status
- Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
- The Drug Rediscovery Protocol (DRUP Trial)
- Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
- A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM)
- An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of HLX07,in Patients With Advanced Solid Cancers
- Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
- FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
- A Trial of Trametinib and Panitumumab in RAS/RAF Wild Type Advanced Colorectal Cancer
- Panitumumab for Intravenous Infusion 100 mg and 400 mg Special Drug Use Surveillance "Survey on Unresectable, Advanced or Recurrent Colorectal Cancer With Wild-type KRAS Gene" (All-patient Surveillance)
- Cabozantinib and Panitumumab to Treat KRAS Wild-Type Metastatic Colorectal Cancer
- Maintenance Therapy With 5-FU/FA Plus Panitumumab vs. 5-FU/FA Alone After Prior Induction and Re-induction After Progress for 1st-line Treatment of Metastatic Colorectal Cancer
- Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
- A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer
- Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab in Patients With Resectable Liver Metastases
- Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer
- MEGA (Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma): FOLFOX Alone or in Combination With AMG 102 or Panitumumab as First-line Treatment in Patients With Advanced Gastroesophageal Adenocarcinoma
- Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
- Carboplatin-based Chemotherapy With or Without Panitumumab in Platinum-sensitive Recurrent Ovarian Cancer
- Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
- Vectibix for the Treatment of Anal Cancer
- Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus
- CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater
- Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
- Study of Panitumumab in the Treatment of Carcinoid Syndrome
- Safety Study of the Combination of Panitumumab, Irinotecan and Everolimus in the Treatment of Advanced Colorectal Cancer
- Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)
- Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
- Chemoradiation and Panitumumab for Esophageal Cancer
- A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007
- Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC
- Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
- Panitumumab and Irinotecan for Malignant Gliomas
- Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer
- ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
- Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
- Preoperative Panitumumab and Radiotherapy in Rectal Cancer
- Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
- Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
- Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
- Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
- New Individualized Therapy Trial for Metastatic Colorectal Cancer
- Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type
- Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer
- PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
- Capecitabine and Radiation Therapy With or Without Panitumumab in Treating Patients With Advanced Rectal Cancer
- Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer
- Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
- Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
- BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)
- Effect of Panitumumab on the Pharmacokinetics of Irinotecan
- Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
- PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
- Panitumumab Regimen Evaluation in Colorectal Cancer to Estimate Primary Response to Treatment
- Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
- PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
- Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer
- Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Clinical trials list
click for details